PT - JOURNAL ARTICLE AU - Alcoba-Florez, Julia AU - Gil-Campesino, Helena AU - de Artola, Diego García-Martínez AU - González-Montelongo, Rafaela AU - Valenzuela-Fernández, Agustín AU - Ciuffreda, Laura AU - Flores, Carlos TI - Sensitivity of different RT-qPCR solutions for SARS-CoV-2 detection AID - 10.1101/2020.06.23.20137455 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.23.20137455 4099 - http://medrxiv.org/content/early/2020/06/24/2020.06.23.20137455.short 4100 - http://medrxiv.org/content/early/2020/06/24/2020.06.23.20137455.full AB - Objective The ongoing COVID-19 pandemic continues imposing a demand for diagnostic screening. In anticipation that the recurrence of outbreaks and the measures for lifting the lockdown worldwide may cause supply chain issues over the coming months, we assessed the sensitivity of a number of one-step retrotranscription and quantitative PCR (RT-qPCR) solutions to detect SARS-CoV-2.Methods We evaluated six different RT-qPCR alternatives for SARS-CoV-2/COVID-19 diagnosis based on standard RNA extractions. That of best sensitivity was also assessed with direct nasopharyngeal swab viral transmission medium (VTM) heating, overcoming the RNA extraction step.Results We found a wide variability in the sensitivity of RT-qPCR solutions that associated with a range of false negatives from as low as 2% (0.3-7.9%) to as much as 39.8% (30.2-50.2). Direct preheating of VTM combined with the best solution provided a sensitivity of 72.5% (62.5-81.0), in the range of some of the solutions based on standard RNA extractions.Conclusions We evidenced sensitivity limitations of currently used RT-qPCR solutions. Our results will help to calibrate the impact of false negative diagnoses of COVID-19, and to detect and control new SARS-CoV-2 outbreaks and community transmissions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by Cabildo Insular de Tenerife [grant number CGIEU0000219140]; the agreement with Instituto Tecnologico y de Energias Renovables (ITER) to strengthen scientific and technological education, training research, development and innovation in Genomics, Personalized Medicine and Biotechnology [grant number OA17/008]; Ministerio de Innovacion y Ciencia [grant number RTI2018-093747-B-100 and RTC-2017-6471-1], co-funded by the European Regional Development Fund (ERDF); Lab P2+ facility [grant number UNLL10-3E-783], co-funded by the ERDF and Fundacion CajaCanarias; and the Spanish HIV/AIDS Research Network [grant number RIS-RETIC, RD16/0025/0011], co-funded by Instituto de Salud Carlos III and by the ERDF.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University Hospital Nuestra Señora de Candelaria (Santa Cruz de Tenerife, Spain) review board approved the study (ethics approval number: CHUNSC_2020_24).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable.